Last reviewed · How we verify
Pregabalin + Vitamin B fixed dose
Pregabalin binds to voltage-gated calcium channels to reduce neurotransmitter release, while B vitamins support nerve function and myelin integrity.
Pregabalin binds to voltage-gated calcium channels to reduce neurotransmitter release, while B vitamins support nerve function and myelin integrity. Used for Neuropathic pain (diabetic peripheral neuropathy, postherpetic neuralgia, or other peripheral neuropathies), Generalized anxiety disorder, Partial-onset seizures.
At a glance
| Generic name | Pregabalin + Vitamin B fixed dose |
|---|---|
| Also known as | Pre+Vit B |
| Sponsor | Laboratorios Silanes S.A. de C.V. |
| Drug class | Gabapentinoid with B vitamin supplement |
| Target | Alpha-2-delta subunit of L-type voltage-gated calcium channels |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | Phase 3 |
Mechanism of action
Pregabalin is a gabapentinoid that binds to the alpha-2-delta subunit of L-type voltage-gated calcium channels in the central nervous system, reducing the release of excitatory neurotransmitters and thereby decreasing neuronal hyperexcitability. The addition of B vitamins (likely B1, B6, B12) provides nutritional support for nerve metabolism and myelin maintenance, potentially enhancing neuroprotection and symptom relief in neuropathic conditions.
Approved indications
- Neuropathic pain (diabetic peripheral neuropathy, postherpetic neuralgia, or other peripheral neuropathies)
- Generalized anxiety disorder
- Partial-onset seizures
Common side effects
- Dizziness
- Somnolence
- Dry mouth
- Edema
- Blurred vision
- Weight gain
- Ataxia
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: